The following antibodies were used: rabbit anti-Coilin (1:2000; ab210785, Abcam), mouse IgG1 anti-Fibrillarin (1:60; ab4566, Abcam), mouse IgG1 anti-nuclear pore complex proteins MAb414 (1:1000; MMS-120P-100, Eurogentec), rabbit anti-NPAT (1:700; A302–772A, Bethyl Laboratories), mouse IgG1 anti-PSPC1(1:100; clone IL4, SAB4200503, Sigma-Aldrich), rabbit anti-pSF3b155 (phosphorylated at Thr313; 1:400; clone D8D8V, 25009, Cell Signaling), rabbit anti-SF3b155 (1:600; clone D7L5T, 14434, Cell Signaling), mouse IgG1 anti-SMN1 (1:100; Survival of Motor Neurons, clone 2B1, 05–1532, EMD Millipore), mouse IgG1 anti-SRSF2/SC35 (1:400; ab11826, Abcam), mouse IgG1 anti-TDP-43/TARDBP (1:1500; clone 3H8, MABN45, EMD Millipore), and species-specific Alexa Fluor secondary antibodies (1:400; Thermo Fisher). A recent study45 (link) proposed that the main target of the monoclonal SRSF2/SC35 antibodies is SRRM2 instead of SRSF2/SC35. However, SRRM2 is a spliceosome-associated protein that sharply localizes to nuclear speckles45 (link). We also confirmed that the monoclonal ab11826 antibody we used recognized SRS2-GFP+ speckles in fixed oocytes expressing SRSF2-GFP. The conclusions of our study are thus unaffected by the proposed SRSF2/SC35 antibody discrepancy45 (link).
Free full text: Click here